Open prospective study to evaluate the efficacy of a new vaginal pessary containing 300mg tinidazole, 200mg tioconazole and 100mg lidocaine with a 3-day regime (Gynomax XL®) in the treatment of vaginal infections due to bacterial vaginosis, candidiasis an

Authors

  • P.A. Regidor University of Duisburg-Essen, Germany
  • M. Sailer University of Duisburg-Essen, Germany

DOI:

https://doi.org/10.18370/2309-4117.2024.71.117-126

Keywords:

candidiasis, bacterial vaginosis, mixed vaginal infections, tinidazole, tioconazol

Abstract

Introduction. The management of infections of the vulva and vagina depend on the selection and administration of effective specific therapies that allow a fast treatment, enhancing the compliance of the patients.

Objective of the study: the efficacy and safety of a new medicinal product containing 300mg tinidazole/200mg tioconazole/100mg lidocaine for the treatment against vaginal candida albicans, bacterial vaginosis and combined infections was evaluated upon 69 patients.

Materials and methods. Clinical controls, pH, 10% KOH probe, microscopical and microbiological analysis were performed at day 1, day 4, day 10 and at day 30 of the study. Success was defined as follows: 0 points = no symptoms, 1 point = mild symptoms, 2 points = moderate symptoms, 3 points = severe symptoms.

Results. A complete clinical recovery at day 10 was observed in 54 (80.6%) patients. A clinical improvement in 12 (17.9%) and a failure in 1 patient (1,5%). At day 30 a clinical complete recovery was observed in 58 (86.6%) patients, a clinical improvement in 7 (10.4%) and a failure in 2 patients (3%).

Conclusions. This formulation (GynomaxXL), a vaginal suppository given at 3 consecutive days, is a highly effective and safe combination in the therapy of vulvovaginal candidiasis and bacterial vaginosis.

Author Biographies

P.A. Regidor, University of Duisburg-Essen

Department of Gynecology and Obsterics

M. Sailer, University of Duisburg-Essen

Department of Gynecology and Obsterics

References

  1. Brocklehurst P, Mindel A. Recurrent genital infections. Br J Sex Med. 1991 18: 54–7.
  2. Landers DV. The treatment of vaginitis: Trichomonas, yeast, and bacterial vaginosis. Clin Obstet Gynecol. 1988 Jun;31(2):473–9. DOI: 10.1097/00003081-198806000-00021.
  3. Mardh PA, Tchoudomirova K, Elshibly S, Hellberg D. Symptoms and sings in single and mixed genital infections. Int J Gynecol Obstet. 1998 Nov;63(2):145–52. DOI: 10.1016/s0020-7292(98)00140-4.
  4. Govender L, Hoosen AA, Moodley J, et al. Bacterial vaginosis and associated infections in pregnancy. Int J Gynecol Obstet. 1996. Oct;55(1): 23–28. DOI: 10.1016/0020-7292(96)02744-0
  5. Redondo Lopez V, Meriwether C, Schmitt C, et al. Vulvovaginal candidiais complicating recurrent bacterial vaginosis. Sex Transm Dis. 1990 Jan-Mar;17(1): 51–3.
  6. Blackwell A. Infectious causes of abnormal vaginal discharge – part two. Matern Child Health 1987 12: 368–375. https://doi.org/10.1177/030006059302100104
  7. Ferris DG, Hendrich J, Payne PM, et al. Office laboratory diagnosis of vaginitis. Clinicianperformed tests compared with a rapid nucleic acid hybridization test. J Fam Pract 1995. Dec;41(6): 575–81.
  8. Morton O. Neotran – new double-active pessary for the treatment of vaginitis. J Int Med Res 1993;21:36–46. https://doi.org/10.1177/03000605930210010
  9. Kukner S, Ergin T, Cicek N, et al. Treatment of vaginitis. Int J Gynecol Obstet 1996;52(1): 43–47. DOI: 10.1016/0020-7292(95)02531-6.
  10. Altıntaş A, Embil K. A new pessary for the treatment of vaginitis – clinical trial report (abstract 93.004). 8th Edn. International Congress of Infectious Diseases, Boston, USA. 1998.
  11. Taner C, Yucel ES, İnce M, et al. Vaginitis and treatment (abstract 93.005). 8th Edn. International Congress of Infectious Diseases, Boston, USA. 1998.
  12. Ozyurt E, Toykuliyeva MB, Danilyans IL, et al. Efficacy of 7-day treatment with metronidazole + miconazole (Neo-Penotran) – a triple-active pessary for the treatment of single and mixed vaginal infections. Int J Gynecol Obstet 2001;74(1): 35–43. DOI: 10.1016/s0020-7292(01)00388-5
  13. Huseyinova L, Toykuliyeva MB, Ozyurt E, Danilyans IL, Baktır G. Tolerance, acceptability and absorption study with Neo-Penotran→ Forte-L and Neo-Penotran→ Forte in healthy volunteers (abstract 0158). 10th Edn. International Congress of Infectious Diseases, Singapore. 2002
  14. Regidor PA, Ozyurt E, Toykuliyeva MB, et al. Treatment and prevention of trichomoniasis, bacterial vaginosis and candidiasis with a new 7-day regime containing metronidazole and meiconazole in a single vaginal pessary. IJMDAT 2018;1(1):e118.
  15. Duarte G, Baracat EC, Wehba S. Efficacy and tolerability of tioconazole/tinidazole combination in the treatment of vulovovaginitis. Femina 2016;96(24):895–904.
  16. Tinidazole, Micromedex. Healthcare Series [Internet database]. Greenwood Village, Colo: Thomson Reuters (Healthcare). Updated periodically. 2010.
  17. Mattila J, Mannisto PT, Mantyla R, et al. Comparative pharmacokinetics of metrinidazole and tinidazole as influenced by administration route. Antimicrobial agents and chemotherapy. 1993. May;23: 721–5. DOI: 10.1128/AAC.23.5.721.
  18. Jevons S, Gymer, GE, Brammer KW, et al. Antifungal activity of tioconazole (UK-20,349), a new imidazole derivate. Antimicrobial agents Chemotherapy 1979 Apr;15(4):597–602. DOI: 10.1128/AAC.15.4.597.
  19. Morton O. Neotran – new double-active pessary for the treatment of vaginitis. J Int Med Res 1993;21:36–46. https://doi.org/10.1177/03000605930210010
  20. Houang ET, Lawrence A. Systemic absorption and persistence of tioconazole in vaginal fluid after insertion of a single 300- mg tioconazole ovule. Antimicrobila Agents and Chemotherapy 1995;27: 964–5.
  21. Borchardt, Kenneth A. Sexually transmitted diseases: epidemiology, pathology, diagnosis, and treatment. CRC Press, Boca Raton, Florida, 1997:p. 4.
  22. Donders GG, Zodzika J, Rezeberga D. Treatment of bacterial vaginosis: what we have and what we miss. Expert opinion on pharmacotherapy 2014 Apr;15(5):645–57. DOI: 10.1517/14656566.2014.881800.
  23. Sharma H, Tal R, Clark NA, Segars JH. Microbiota and Pelvic Inflammatory Disease. Seminars in Reproductive Medicine 2014 Jan;32(01):43–9.
  24. What are the symptoms of bacterial vaginosis? National Institute of Child Health and Human Development. 2013 May 21. [Retrieved 3 March 2015].
  25. Kenyon C, Colebunders R, Crucitti T. The global epidemiology of bacterial vaginosis: a systematic review. Am J Obstet Gynecol. 2013 Dec;209(6):505–23. DOI: 10.1016/j.ajog.2013.05.006
  26. Bradshaw CS, Brotman RM. Making inroads into improving treatment of bacterial vaginosis – striving for long-term cure. BMC Infect Dis. 2015 Jul 29;15:292. DOI: 10.1186/s12879-015-1027-4
  27. Queenan JT, Spong CY, Lockwood CJ. Queenan’s management of high-risk pregnancy: an evidence-based approach [6th ed.]. Chichester, West Sussex: Wiley-Blackwell, 2012:p.262.
  28. What are the treatments for bacterial vaginosis (BV)? National Institute of Child Health and Human Development. 2015. [Last Reviewed Date5/5/2021].
  29. Bennett J. Mandell, Dolin R. Douglas, and Bennett’s principles and practice of infectious diseases. Philadelphia, PA: Elsevier/Saunders, 2015:p.4028.
  30. Bacterial Vaginosis (BV): Condition Information. National Institute of Child Health and Human Development. 2015
  31. Nardis C, Mastromarino P, Mosca L. Vaginal microbiota and viral sexually transmitted diseases. Annali di Igiene. 2013 Sep-Oct;25 (5):443–56. DOI: 10.7416/ai.2013.1946.
  32. Bacterial Vaginosis – CDC Fact Sheet. Centers for Disease Control and Prevention. 2014
  33. Mashburn J. Etiology, diagnosis, and management of vaginitis. Journal of midwifery & women’s health 2006 Nov- Dec;51(6):423–30. DOI: 10.1016/j.jmwh.2006.07.005.
  34. Mulley AG, Goroll AH. Primary Care Medicine: office evaluation and management of the adult patient. Philadelphia: Wolters Kluwer Health. 2006: p.802–3.
  35. Goehring RV. Mims’ medical microbiology. [4th Edn.]. Mosby Elsevier, Philadelphia, USA, 2008:p.656.
  36. Nwokolo NC, Boag FC. Chronic vaginal candidiasis. Management in the postmenopausal patient. Drugs Aging. 2000 16(5): 335–339.
  37. Bassetti M, Mikulska M, Viscoli C. Bench-to-bedside review: therapeutic management of invasive candidiasis in the intensive care unit. Critical Care. 2010 14(6):244. DOI: 10.1186/cc9239
  38. Odds FC. Candida infections: an overview. Crit Rev Microbiol. 1987 15(1):1–5.
  39. Choo ZW, Chakravarthi S, Wong SF, et al. A comparative histopathological study of systemic candidiasis in association with experimentally induced breast cancer. Oncology Letters 2010 Jan 1(1): 215–222. DOI: 10.3892/ol_00000039
  40. Akpan A, Morgan R. Oral candidiasis. Postgraduate Medical Journal 2002 Aug;78(922): 455–459. DOI: 10.1136/pmj.78.922.455.
  41. AHFS Drug Information. American Society of Health-System Pharmacists, Bethesda, MD, 2010:p.3522.
  42. Dunne RL, Dunn LA, Upcroft P, et al. Drug resistence in the sexually transmitted protozoan Trichonomas vaginalis. Cell res 2003 Aug;13(4):239–49. DOI: 10.1038/sj.cr.7290169.
  43. Sobel JD, Nyirjesy P, Brown W. Tinidazole therapy for metronidazole-resistant vaginal trichomoniasis. Clin Infect Dis. 2001 Oct;33(8): 1341–6. DOI: 10.1086/323034.

Downloads

Published

2024-03-15

How to Cite

Regidor, P., & Sailer, M. (2024). Open prospective study to evaluate the efficacy of a new vaginal pessary containing 300mg tinidazole, 200mg tioconazole and 100mg lidocaine with a 3-day regime (Gynomax XL®) in the treatment of vaginal infections due to bacterial vaginosis, candidiasis an. REPRODUCTIVE ENDOCRINOLOGY, (71), 117–126. https://doi.org/10.18370/2309-4117.2024.71.117-126

Issue

No. 71 (2024)

Section

Scientific Studies

License

Copyright (c) 2024 P.A. Regidor, M. Sailer

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.